There were 169,761 subjects who participated in the OSCS in the years 20, and, of those cases, 8282 successfully stopped smoking.Ģ. The costs measured include cost to the health sector, non-health sectors, the patients, and their family, as well as loss of productivity as a result of smoking Benefits measures include the medical costs savings and the earnings due to the increased life expectancy of a person who has stopped smoking for 15 yearsġ. To evaluate the costs and benefits of the Outpatient Smoking Cessation Services (OSCS) program in Taiwan from a societal view pointĬost–benefit analysis primary and secondary data sensitivity analyses Web, PTC, and combined PTC–Web treatments were all highly cost effective, with the Web treatment being marginally more cost effective than the PTC or combined PTC–Web treatments.
Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments.ĥ. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were US$1,148 and US$1,136 for Web, US$1,320 and US$1,308 for PTC, and US$1,450 and US$1,437 for PTC–Web.Ĥ. Costs per additional 6-month nonsmoker and per additional lifetime quitter were US$1,278 and US$2,601 for Web, US$1,472 and US$2,995 for PTC, and US$1,617 and US$3,291 for PTC–Web.ģ. The Web intervention was the least expensive followed by the PTC and PTC–Web groups.Ģ. To evaluate the cost effectiveness of varencline and three different behavioral treatment formats for smoking cessation: proactive telephone counseling (PTC), Web-based program, and a combination of PTC and web-based programīehavioral intervention cost effectiveness analysis sensitivity analysesĪverage cost of telephone minute costs per enrollee for the Web group varenicline drug cost per enrollee cost per lifetime quitter cost per additional 6 months nonsmoker and additional lifetime quitter cost per LY and QALYġ. When considering 8-year quit rates, the cost per life year saved was estimated at US$128 in the base scenario and increased to US$230 in the worst case scenario. Cost per service user who maintained cessation at 4 weeks, 6 months, and 1 year was US$76, US$149 and US$212, respectively.Ĥ. Cost per service user who set a quit date was US$60. The cost of the service in 2009 was US$21,127. Estimated 1-year and 8-year quit rates were 28.1% and 12.9%, respectively.ģ. The self-reported 4-week and 6-month quit rates were 78% and 40%, respectively.
A total of 354,554 smokers used the Smoking Cessation Clinics in 2009.Ģ. Self-reported quit rates cost per quitter cost per service user cost per life-year savedġ. To evaluate the cost and effectiveness of the nationwide government-sponsored smoking cessation clinicsĬost-effectiveness analysis sensitivity analysis Including indirect cost and benefits of smoking cessation interventions further strengthens the result with the extended course of varenicline dominating all other alternatives considered. Compared with the standard varenicline treatment course, the extended course is highly cost effective with an incremental cost–effectiveness ratio (ICER) less than US$4,000 per quality-adjusted life year (QALY).ģ. Over the subjects’ life time, both the standard and the extended course of varenicline are shown to dominate (eg, less costly and more effective) all other alternative smoking cessation interventions considered.Ģ. Incremental cost–effectiveness ratio per quality-adjusted life year (QALY)ġ. To evaluate the long-term cost effectiveness of varenicline compared with other smoking cessation interventions in Canadaīenefits of Smoking Cessation on Outcomes (BENESCO) model Markov cohort model
0 kommentar(er)
